Breast NeoplasmsBROWSENCT02608593
Breast Reconstruction Outcomes With and Without StratticE
An observational study of Breast Neoplasms, run by Manchester University NHS Foundation Trust.
Trial summary
Approximately 4,000 women undergo a mastectomy for breast cancer each year in the UK and around 1,500 will have an immediate breast reconstruction. Approximately half of these ladies will have an implant-based breast reconstruction, of which many have an "implant-assisted" breast reconstruction with an Acellular… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Neoplasms
- What is being tested?
- Strattice
- Type of treatment
- Surgery or procedure
- How many people
- 121 participants
- Where
- No sites listed yet
- Study dates
- 19 Aug 2016to 31 Oct 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: * Patients age 18 years or older at the time of surgery. * Patients who have undergone immediate Implant-based breast reconstruction with or without Strattice™ with a minimum follow-up of six months. * Patients capable of providing informed consent.
Who may be able to join
- Patients age 18 years or older at the time of surgery.
- Patients who have undergone immediate Implant-based breast reconstruction with or without Strattice™ with a minimum follow-up of six months.
- Patients capable of providing informed consent.
Who cannot join
- Patients who have had an immediate implant-based breast reconstruction with an alternative brand of matrix/mesh to Strattice™.
- Patients who have had a flap based-reconstruction with implant.
- Delayed reconstructions.
About this study
Official title: Breast Reconstruction Outcomes With and Without StratticE (BROWSE)
Approximately 4,000 women undergo a mastectomy for breast cancer each year in the UK and around 1,500 will have an immediate breast reconstruction. Approximately half of these ladies will have an implant-based breast reconstruction, of which many have an "implant-assisted" breast reconstruction with an Acellular Dermal Matrix.
Strattice™ is an Acellular Dermal Matrix (a pig skin product) made by Acelity. It is used to cover and disguise the lower part of the breast implant. Acellular Dermal Matrices have only been widely used for the last eight years and long-term outcomes for women who have had this form of reconstruction are lacking. Despite this, it is one of the most commonly offered methods of breast reconstruction in the UK for both ladies with a diagnosis of breast cancer and in the risk-reduction setting.
The objective of this study is to assess long-term outcomes of Strattice™-based breast reconstructions in multiple Breast Surgery Centres across the UK. This will be a case-control study comparing women who have had an immediate implant-based breast reconstruction with Strattice™ (case) or without (control). This will be achieved by review and analysis of retrospective data from patients who have undergone immediate breast reconstruction using implants with or without Strattice™ following either a diagnosis breast cancer or for risk-reduction. In addition there will be a prospective clinical assessment of the reconstruction outcomes. Outcomes assessed will include complications, surgical re-interventions and aesthetic results. These will be related to co-morbid conditions and other risk factors. Data will also be collected on unplanned interventions associated with a cost, if available.
Read the detailed description
Primary Outcome The primary outcome measure will be unexpected loss of the implant.
Secondary Outcomes
To investigate short and long-term outcomes with Strattice™ including:
- Quality of Life
- In-patient treatment costs
- Ipsilateral Revision rates
- Aesthetic outcome
- Breast reconstruction softness (Tonometry)
- Regional pain
- Loco-regional recurrence
- Effect of radiotherapy
- Complications - (seroma drainage, skin necrosis/ wound breakdown)
Study Design
- All patients who have had an immediate implant-based breast reconstruction will be identified from prospective databases.
- Patients will be invited to enter the research study by post. The invitation letter will include: an offer to take part in the study, a Patient Information Leaflet, a Stamped addressed envelope and an Accept/Decline outcome form.
- If they fail to respond, patients will be re-contacted on one further occasion, in the same manner, after approximately two months.
- Patients will be invited to attend a clinical appointment at the Breast Surgery Centre where their reconstruction was performed. Here they will see a clinical researcher in the presence of a clinic nurse and consent to participate in the study.
- Patients will be asked to undergo a clinical assessment, Tonometry (measurement of breast reconstruction softness) and medical photography. The data obtained from this will be anonymised and inputted into a database for analysis.
- Patients will receive a postal questionnaire following the clinic visit asking them about the "Patient Reported Outcomes" of their reconstruction. (This will not be performed at the clinic visit in an attempt to avoid bias). They will receive a further follow-up questionnaire 12 months later.
- The medical records of patients will be reviewed to assess outcomes including complications from surgery.
- If a patient does not consent for the prospective part of the study, a retrospective audit of their notes for implant loss, revisions and complications will be performed
- All data will be collected on Case Report Forms. Study numbers will be allocated, and linked-anonymised data inputted into a database on a NHS computer for analysis.
- Medical records, including clinic letters, nursing records and anaesthetic charts will be reviewed to collect data on:
- Patient demographics (age, BMI, comorbidities and smoking history at time of surgery)
- Surgical details (operation type, operation time, mastectomy weight, implant size/type)
- Details on cancer outcome and adjuvant therapies
- Post-operative complications (including need for reoperation, prolonged healing, loss of implant)
- Additional prospective data analysed will include:
- Patient Reported Outcome questionnaire results
- Tonometry (breast softness)
- Baker Capsular Contracture grade
- Aesthetic outcome (using Likert score) This will be assessed by the clinical researcher, and independently assessed using the medical photographs, with the assessor blinded to the reconstruction technique
Assessment of Contracture Using the Baker Breast Contracture Scale, the researcher will assess the Baker Grade for each breast to assess the level of capsular contracture.
Baker Grade Parameters I the breast is normally soft and looks natural II the breast is a little firm but looks normal III the breast is firm and looks abnormal IV the breast is hard, painful, and looks abnormal
Inclusion Criteria
- Patients age 18 years or older at the time of surgery.
- Patients who have undergone immediate Implant-based breast reconstruction with or without Strattice™ with a minimum follow-up of six months.
- Patients capable of providing informed consent.
Exclusion Criteria
- Patients who have had an immediate implant-based breast reconstruction with an alternative brand of matrix/mesh to Strattice™.
- Patients who have had a flap based-reconstruction with implant.
- Delayed reconstructions.
Study Size and Statistical Analysis
- From three large breast units across the UK, we shall aim to recruit a maximum of 400 patients to the prospective part of the study.
- Statistical Analysis will be performed in collaboration with Dr Julie Morris, Honorary Senior Lecturer, Department of Medical Statistics. SPSS 15 will be used to analyse the data.
Study Sites:
University Hospital of South Manchester Newcastle Upon Tyne Hospitals NHS Trust Bradford Teaching Hospitals NHS Foundation Trust
- Conditions
- Breast Neoplasms
- Being tested
- Strattice
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
StratticeProcedure or surgery
Implant based reconstruction with strattice cover of part or all of implant
| Study group | Role | What they receive |
|---|---|---|
| Implant reconstruction with Strattice | Women having immediate breast reconstruction with partial or total Strattice cover Receives: Procedure: Strattice | |
| Implant reconstruction without Strattice | Women having immediate implant based breast reconstruction where no Strattice has been used |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients planned loss of implant within 12 months of immediate reconstruction
Measured: 12 months
Secondary outcomes (8)
Quality of Life questionnaire
Measured: 8 years
In-patient treatment costs
Measured: 8 years
Ipsilateral Revision rates
Measured: 1-8 years
Cosmesis
Cosmesis domains of Breast-Q quality of life questionnaire and likert 1-5 scale
Measured: 1-8 years
Breast Reconstruction softness
Using tonometric measurement of breast softness
Measured: 1-8 years
Regional pain
Using pain domain of Breast-Q Quality of Life questionnaire
Measured: 1-8 years
loco-regional cancer recurrence
Measured: 1-8 years
Morbidity
Measured: 1-8 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2015 (estimated)
- Study start19 Aug 2016
- Primary completion31 Oct 2019
- Study completion31 Oct 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 121 participants (actual)
Sponsor and investigators
- Lead sponsor
- Manchester University NHS Foundation Trust
- Sponsor type
- Other government
- Collaborators
- LifeCell
- Responsible party
- Sponsor
- Investigators
- Richard Johnson, Principal investigator, University Hospital of South Manchester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02608593
- Sponsor's protocol ID
- BROWSE
- Acronym
- BROWSE
- Status last verified
- May 2020
- First submitted
- 26 Oct 2015
- Last updated
- 22 May 2020
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Breast Reconstruction Outcomes With and Without StratticE (BROWSE)
- ClinicalTrials.gov ID
- NCT02608593
- Acronym / sponsor ID
- BROWSE / BROWSE
- Conditions
- Breast Neoplasms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 121 participants (actual)
- Lead sponsor
- Manchester University NHS Foundation TrustOther government
- Collaborators
- LifeCell
- Study start
- 19 Aug 2016 (actual)
- Primary completion
- 31 Oct 2019 (actual)
- Study completion
- 31 Oct 2019 (actual)
- First posted
- 18 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Approximately 4,000 women undergo a mastectomy for breast cancer each year in the UK and around 1,500 will have an immediate breast reconstruction. Approximately half of these ladies will have an implant-based breast reconstruction, of which many have an "implant-assisted" breast reconstruction with an Acellular Dermal Matrix.
Strattice™ is an Acellular Dermal Matrix (a pig skin product) made by Acelity. It is used to cover and disguise the lower part of the breast implant. Acellular Dermal Matrices have only been widely used for the last eight years and long-term outcomes for women who have had this form of reconstruction are lacking. Despite this, it is one of the most commonly offered methods of breast reconstruction in the UK for both ladies with a diagnosis of breast cancer and in the risk-reduction setting.
The objective of this study is to assess long-term outcomes of Strattice™-based breast reconstructions in multiple Breast Surgery Centres across the UK. This will be a case-control study comparing women who have had an immediate implant-based breast reconstruction with Strattice™ (case) or without (control). This will be achieved by review and analysis of retrospective data from patients who have undergone immediate breast reconstruction using implants with or without Strattice™ following either a diagnosis breast cancer or for risk-reduction. In addition there will be a prospective clinical assessment of the reconstruction outcomes. Outcomes assessed will include complications, surgical re-interventions and aesthetic results. These will be related to co-morbid conditions and other risk factors. Data will also be collected on unplanned interventions associated with a cost, if available.
Detailed description
Primary Outcome The primary outcome measure will be unexpected loss of the implant.
Secondary Outcomes
To investigate short and long-term outcomes with Strattice™ including:
- Quality of Life
- In-patient treatment costs
- Ipsilateral Revision rates
- Aesthetic outcome
- Breast reconstruction softness (Tonometry)
- Regional pain
- Loco-regional recurrence
- Effect of radiotherapy
- Complications - (seroma drainage, skin necrosis/ wound breakdown)
Study Design
- All patients who have had an immediate implant-based breast reconstruction will be identified from prospective databases.
- Patients will be invited to enter the research study by post. The invitation letter will include: an offer to take part in the study, a Patient Information Leaflet, a Stamped addressed envelope and an Accept/Decline outcome form.
- If they fail to respond, patients will be re-contacted on one further occasion, in the same manner, after approximately two months.
- Patients will be invited to attend a clinical appointment at the Breast Surgery Centre where their reconstruction was performed. Here they will see a clinical researcher in the presence of a clinic nurse and consent to participate in the study.
- Patients will be asked to undergo a clinical assessment, Tonometry (measurement of breast reconstruction softness) and medical photography. The data obtained from this will be anonymised and inputted into a database for analysis.
- Patients will receive a postal questionnaire following the clinic visit asking them about the "Patient Reported Outcomes" of their reconstruction. (This will not be performed at the clinic visit in an attempt to avoid bias). They will receive a further follow-up questionnaire 12 months later.
- The medical records of patients will be reviewed to assess outcomes including complications from surgery.
- If a patient does not consent for the prospective part of the study, a retrospective audit of their notes for implant loss, revisions and complications will be performed
- All data will be collected on Case Report Forms. Study numbers will be allocated, and linked-anonymised data inputted into a database on a NHS computer for analysis.
- Medical records, including clinic letters, nursing records and anaesthetic charts will be reviewed to collect data on:
- Patient demographics (age, BMI, comorbidities and smoking history at time of surgery)
- Surgical details (operation type, operation time, mastectomy weight, implant size/type)
- Details on cancer outcome and adjuvant therapies
- Post-operative complications (including need for reoperation, prolonged healing, loss of implant)
- Additional prospective data analysed will include:
- Patient Reported Outcome questionnaire results
- Tonometry (breast softness)
- Baker Capsular Contracture grade
- Aesthetic outcome (using Likert score) This will be assessed by the clinical researcher, and independently assessed using the medical photographs, with the assessor blinded to the reconstruction technique
Assessment of Contracture Using the Baker Breast Contracture Scale, the researcher will assess the Baker Grade for each breast to assess the level of capsular contracture.
Baker Grade Parameters I the breast is normally soft and looks natural II the breast is a little firm but looks normal III the breast is firm and looks abnormal IV the breast is hard, painful, and looks abnormal
Inclusion Criteria
- Patients age 18 years or older at the time of surgery.
- Patients who have undergone immediate Implant-based breast reconstruction with or without Strattice™ with a minimum follow-up of six months.
- Patients capable of providing informed consent.
Exclusion Criteria
- Patients who have had an immediate implant-based breast reconstruction with an alternative brand of matrix/mesh to Strattice™.
- Patients who have had a flap based-reconstruction with implant.
- Delayed reconstructions.
Study Size and Statistical Analysis
- From three large breast units across the UK, we shall aim to recruit a maximum of 400 patients to the prospective part of the study.
- Statistical Analysis will be performed in collaboration with Dr Julie Morris, Honorary Senior Lecturer, Department of Medical Statistics. SPSS 15 will be used to analyse the data.
Study Sites:
University Hospital of South Manchester Newcastle Upon Tyne Hospitals NHS Trust Bradford Teaching Hospitals NHS Foundation Trust
Study design
- Observational model
- Case-control
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Implant reconstruction with Strattice | – | Procedure: StratticeWomen having immediate breast reconstruction with partial or total Strattice cover |
| Implant reconstruction without Strattice | – | –Women having immediate implant based breast reconstruction where no Strattice has been used |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- * Patients age 18 years or older at the time of surgery. * Patients who have undergone immediate Implant-based breast reconstruction with or without Strattice™ with a minimum follow-up of six months. * Patients capable of providing informed consent.
Key inclusion criteria (3 listed)
- Patients age 18 years or older at the time of surgery.
- Patients who have undergone immediate Implant-based breast reconstruction with or without Strattice™ with a minimum follow-up of six months.
- Patients capable of providing informed consent.
Key exclusion criteria (3 listed)
- Patients who have had an immediate implant-based breast reconstruction with an alternative brand of matrix/mesh to Strattice™.
- Patients who have had a flap based-reconstruction with implant.
- Delayed reconstructions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| StratticeImplant based reconstruction with strattice cover of part or all of implant | Procedure or surgery | Implant reconstruction with Strattice |
Primary outcome
Percentage of patients planned loss of implant within 12 months of immediate reconstruction
Time frame: 12 months
8 secondary outcomes
Quality of Life questionnaire
Time frame: 8 years
In-patient treatment costs
Time frame: 8 years
Ipsilateral Revision rates
Time frame: 1-8 years
Cosmesis
Time frame: 1-8 years
Breast Reconstruction softness
Time frame: 1-8 years
Regional pain
Time frame: 1-8 years
loco-regional cancer recurrence
Time frame: 1-8 years
Morbidity
Time frame: 1-8 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2020.
Related trials for Breast Neoplasms
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingPhase 2
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Breast Neoplasms, Advanced Breast Cancer
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Active, not recruitingPhase 2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Breast Cancer Stage IV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Johnson principal investigator
University Hospital of South Manchester
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Neoplasms, run by Manchester University NHS Foundation Trust.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 May 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients planned loss of implant within 12 months of immediate reconstruction (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2020.